Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background Automated closed-loop control delivery of insulin, also known as the artificial pancreas, is emerging as a treatment option for type 1 diabetes, which is considered generally superior to sensor-augmented insulin pump therapy. Evening and overnight closed-loop control might account for most of the benefits of 24/7 continuous closed-loop control; however, to our knowledge, no direct comparison of these systems has yet been done. In this study, we sought to compare different configurations of a closed-loop control system with activation of automated insulin delivery during the evening and overnight hours compared with continuous 24/7 closed-loop control, and both treatment modalities compared with sensor-augmented insulin pump use. Methods In this randomised crossover trial at the University of Virginia (Charlottesville, VA, USA), we randomly assigned (1:1) participants aged 18 to up to 70 years with a diagnosis of type 1 diabetes for at least 1 year to one of two sequences of four 8-week treatment sessions: sensor-augmented insulin pump therapy, evening and overnight closed-loop control, continuous 24/7 closed-loop control, and evening and overnight closed-loop control (group A) or evening and overnight closed-loop control, continuous 24/7 closed-loop control, evening and overnight closed-loop control, and sensor-augmented pump therapy (group B). Randomisation was done by non-clinical study staff using a computer-generated sequence of Bernoulli trials. The primary outcome of the study was the difference in the percentage of time continuous glucose monitored glucose was less than 3·9 mmol/L (70 mg/dL) during sensor-augmented pump therapy compared with evening and overnight closed-loop control. Our overall analysis followed a modified intention-to-treat approach, with all available data for participants who had completed at least two study sessions included in the analysis, regardless of actual use of a closed-loop control device. The trial was registered with ClinicalTrials.gov, NCT02679287. Findings Between April 21, 2016, and June 1, 2018, we assessed 103 patients for eligibility and 93 were randomly assigned to group A (n=47) or group B (n=46). Our final analysis included 80 participants who had completed at least two study phases (40 in group A and 40 in group B). Compared with sensor-augmented pump therapy sessions, evening and overnight closed-loop control sessions reduced the mean overall (day and night) percentage of time blood glucose was less than 70 mg/dL (3·9 mmol/L) from 4·0% (SD 3·3) to 2·2% (1·8), an absolute difference of −1·8% (95% CI 1·2–2·4; p<0·0001). This was accompanied by an overall reduction in HbA 1c from mean 7·4% (SD 1·0) at baseline to 7·1% (0·9) at the end of the study, resulting in an absolute difference of −0·3% (95% CI 0·1–0·4%; p<0·0001). We observed no cases of diabetic ketoacidosis. There were three cases of hyperglycaemia with ketosis that did not meet the criteria for diabetic ketoacidosis, all of which were treated at home with insulin and oral fluid, without known malfunction of the investigational device. There were five cases of severe hypoglycaemia attributed to user-directed boluses without malfunction of the investigational device. Interpretation In type 1 diabetes, evening and overnight closed-loop control was superior to sensor-augmented pump therapy, achieving most of the glycaemic benefits of 24/7 continuous closed-loop control. Our findings could offer people with type 1 diabetes more flexibility in treatment options with use of automated insulin delivery systems at varying times of day. Funding National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases. Roche, Tandem Diabetes Care, and Dexcom provided material support.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Self-citation6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s006 · Cited by 655
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“In the past three years: (i) a pivotal trial of the first commercial hybrid CLC system was completed – the Medtronic 670G which automatically modulates basal rates but not insulin boluses [9] – and the system was cleared by the FDA for clinical use; (ii) a six-month feasibility study reported improvement in glycemic c…”
BackgroundWeisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440 · cited 2×
“More recently, two studies using different algorithms implemented in Android smart phones, reported mobile AP use of 12 weeks by significant number of participants – 86 [19] and 68 [20], respectively.”
BackgroundBekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Metrics for glycaemic control - from HbA1c to continuous glucose monitoring
Kovatchev, B. P. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.3 · Cited by 272
Self-citationBenhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217
Breton, M. D., Cherñavvsky, D. R., Forlenza, G. P., DeBoer, M. D., Robic, J., Wadwa, R. P., Messer, L. H., Kovatchev, B. P., & Maahs, D. M. (2017) · Diabetes Care · doi:10.2337/dc17-0883 · Cited by 179 · cited 11×
“Eligibility: T1D for at least 1 year, using an insulin pump for at least six months, ages 18 years or older.”
BackgroundInfluentialSelf-citation
Cited by
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac022 · Cited by 443
Self-citationOne Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology
Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0097 · Cited by 250
Self-citationJacobs, P. G., Herrero, P., Facchinetti, A., Vehi, J., Kovatchev, B., Breton, M. D., Cinar, A., Nikita, K. S., Doyle, F. J., Bondia, J., et al. (2024) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2023.3331297 · Cited by 113
Self-citationJiao, X., Shen, Y., & Chen, Y. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002633 · Cited by 76
“A meta-analysis of adverse events (severe hypoglycemic events, hyperglycemic events, and diabetic ketoacidosis events) in the CLS and control groups found no significant difference in the risk of these adverse events between the two groups (online supplemental appendix 16).”
Fang, Z., Liu, M., Tao, J., Li, C., Zou, F., & Zhang, W. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01674-6 · Cited by 38
Metadata
- Authors
- Kovatchev, B. P., Kollar, L., Anderson, S. M., Barnett, C., Breton, M. D., Carr, K., Gildersleeve, R., Oliveri, M. C., Wakeman, C. A., & Brown, S. A.
- Venue
- The Lancet Digital Health
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 2
- Issue
- 2
- Pages
- e64-e73
- ISSN
- 2589-7500 (ISSN-L)
- OpenAlex
- W2998526207
- Cited by
- 47
- References
- 17
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial. https://app.cochat.ai/papers/10.1016/s2589-7500(19)30218-3
- The paper
- Kovatchev, B. P., Kollar, L., Anderson, S. M., Barnett, C., Breton, M. D., Carr, K., Gildersleeve, R., Oliveri, M. C., Wakeman, C. A., & Brown, S. A. (2020). Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial. The Lancet Digital Health. https://doi.org/10.1016/s2589-7500(19)30218-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.